Conception

Biotech firm developing egg cells from blood

Berkeley, California, United States

About Conception

Conception.bio focuses on improving fertility treatments through advanced biotechnology. The company has developed a method to create viable egg cells from blood samples by transforming induced pluripotent stem cells (iPSCs) into mature egg cells. This process allows women to extend their fertility, provides new options for couples facing infertility, and enables genetic screening of embryos to avoid hereditary diseases. Unlike other fertility treatment providers, Conception.bio directly serves individuals and couples, including same-sex male couples, with a unique approach to egg cell development. The goal is to lead the fertility treatment market by offering effective solutions that address the diverse needs of those seeking to conceive.

Berkeley, CaliforniaHeadquarters
2017Year Founded
$23MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Company Equity
Flexible Work Hours

Risks

Ethical concerns about iPSCs may lead to public backlash and regulatory challenges.
Competition from companies like Dioseve could impact Conception's market share.
Legal challenges in iPSC and fertility treatment IP rights could arise.

Differentiation

Conception turns skin cells into viable human eggs, a groundbreaking fertility innovation.
Their technology offers fertility solutions for women, infertile couples, and same-sex male couples.
Conception's iPSC-based approach allows for genetic screening and potential disease prevention.

Upsides

Growing interest in genetic screening boosts demand for Conception's reproductive technologies.
Advancements in CRISPR enhance Conception's potential for genetic disease prevention.
Fertility treatment market growth presents significant opportunities for Conception's solutions.